About
CartiHeal develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal's cell-free, off-the-shelf implant, Agili-C, is CE marked for use in cartilage and osteochondral defects. Agili-C is a rigid, biphasic, biodegradable implant. The bone phase of the implant is composed of calcium carbonate in aragonite crystalline form, a well-known biomaterial that enhances bone formation. The cartilage phase is a composite of modified aragonite and hyaluronic acid. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle, and big toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In October 2020, the the Agili-C implant was granted breakthrough device designation by the US FDA.